Precision BioSciences, Inc.

DTIL Healthcare Biotechnology

Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024.

Revenue
+37,272.4%
EPS
+85.0%
Free cash flow
−0.52%
Total debt
+0.22%

Quarter to September 2026, against a year earlier

10.75 0.88 +8.92%
Market cap
$275.7M
P/E
0.0×
Fwd P/E
−2.9×
Dividend yield
—
F-score
1/9
Altman Z
−4.31
Beneish M
n/a
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
ROE

+8 more TTM periods

(61.52%) (69.52%) (132.91%) (112.69%)
Piotroski F-Score
1 2 — —
ROA
(31.45%) (32.50%) (44.91%) (36.04%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(41.10%) (42.69%) (61.77%) (48.74%)
Average Days of Receivables
0.00 32.39 — —
Free Cash Flow per Share
(5.18) (2.40) (2.02) (1.91)
Free Cash Flow
(66.48) (59.16) (52.32) (52.40)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026